Skip to content

Other Select Adverse Reactions

Most common (≥20%) adverse reactions, including lab abnormalities

HER2+ and HER2-low mBC, HER2-mutant NSCLC, and solid tumors (including IHC 3+)
(n=1799; 5.4 mg/kg)1,a
HER2+ aGC
(n=125; 6.4 mg/kg)1,b
  • Nausea (73%)
  • Decreased white blood cell count (70%)
  • Decreased hemoglobin (66%)
  • Decreased neutrophil count (63%)
  • Decreased lymphocyte count (58%)
  • Fatigue (56%)
  • Decreased platelet count (48%)
  • Increased aspartate aminotransferase (47%)
  • Increased alanine aminotransferase (43%)
  • Vomiting (40%)
  • Increased blood alkaline phosphatase (38%)
  • Alopecia (34%)
  • Constipation (33%)
  • Decreased appetite (32%)
  • Decreased blood potassium (31%)
  • Diarrhea (29%)
  • Musculoskeletal pain (24%)
  • Abdominal pain (20%)
  • Decreased hemoglobin (75%)
  • Decreased white blood cell count (74%)
  • Decreased neutrophil count (72%)
  • Decreased lymphocyte count (70%)
  • Decreased platelet count (68%)
  • Nausea (63%)
  • Decreased appetite (60%)
  • Anemia (58%)
  • Increased aspartate aminotransferase (58%)
  • Fatigue (55%)
  • Increased blood alkaline phosphatase (54%)
  • Increased alanine aminotransferase (47%)
  • Diarrhea (32%)
  • Decreased blood potassium (30%)
  • Vomiting (26%)
  • Constipation (24%)
  • Increased blood bilirubin (24%)
  • Pyrexia (24%)
  • Alopecia (22%)
HER2+ and HER2-low mBC, HER2-mutant NSCLC, and solid tumors (including IHC 3+)
(n=1799; 5.4 mg/kg)1,a
  • Nausea (73%)
  • Decreased white blood cell count (70%)
  • Decreased hemoglobin (66%)
  • Decreased neutrophil count (63%)
  • Decreased lymphocyte count (58%)
  • Fatigue (56%)
  • Decreased platelet count (48%)
  • Increased aspartate aminotransferase (47%)
  • Increased alanine aminotransferase (43%)
  • Vomiting (40%)
  • Increased blood alkaline phosphatase (38%)
  • Alopecia (34%)
  • Constipation (33%)
  • Decreased appetite (32%)
  • Decreased blood potassium (31%)
  • Diarrhea (29%)
  • Musculoskeletal pain (24%)
  • Abdominal pain (20%)

HER2+ aGC
(n=125; 6.4 mg/kg)1,b

  • Decreased hemoglobin (75%)
  • Decreased white blood cell count (74%)
  • Decreased neutrophil count (72%)
  • Decreased lymphocyte count (70%)
  • Decreased platelet count (68%)
  • Nausea (63%)
  • Decreased appetite (60%)
  • Anemia (58%)
  • Increased aspartate aminotransferase (58%)
  • Fatigue (55%)
  • Increased blood alkaline phosphatase (54%)
  • Increased alanine aminotransferase (47%)
  • Diarrhea (32%)
  • Decreased blood potassium (30%)
  • Vomiting (26%)
  • Constipation (24%)
  • Increased blood bilirubin (24%)
  • Pyrexia (24%)
  • Alopecia (22%)

aThe pooled safety population reflects exposure to ENHERTU 5.4 mg/kg IV every 3 weeks in 1799 patients in Study DS8201-A-J101 (NCT02564900), DB-01, DB-02, DB-03, DB-04, DL-01, DL-02, DC-02, and DP-02.1

bBased on exposure to ENHERTU 6.4 mg/kg IV Q3W in 125 patients in DESTINY-Gastric01.1

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for prophylactic management of nausea and/or vomiting

ENHERTU is highly emetogenic, which includes delayed nausea and/or vomiting. Administer prophylactic antiemetic medications per local institutional guidelines for prevention of chemotherapy-induced nausea and vomiting.1

Premedication is recommended prior to infusion of fam-trastuzumab deruxtecan-nxki (ENHERTU)2

  • The NCCN Guidelines® for Antiemesis recommends 3-4 prophylactic antiemetic regimens for high emetic risk agents, including fam-trastuzumab deruxtecan-nxki (ENHERTU), to help decrease potential nausea/vomitingc-e
  • Consider option A, B, or C
  • All treatments are Category 1 and should be started before anticancer therapyf
Treatment option Day 1 Days
2, 3, and 4
A
(Preferred)g

    Use the following:

  • Olanzapineh
  • NK1 RA
  • 5-HT3 RAi,j
  • Dexamethasonek,l

    Use the following:

  • Olanzapineh on days 2-4
  • Oral aprepitant on days 2-3 (if oral aprepitant is used on day 1)
  • Dexamethasonek,l on days 2-4
B

    Use the following:

  • Olanzapineh
  • Palonosetron
  • Dexamethasonek,l

    Use the following:

  • Olanzapineh on days 2-4
C

    Use the following:

  • NK1 RA
  • 5-HT3 RAi,j
  • Dexamethasonek,l

    Use the following:

  • Oral aprepitant on days 2-3 (if oral aprepitant is used on day 1)
  • Dexamethasonek,l on days 2-4
Treatment option Day 1 Days
2, 3, and 4
A
(Preferred)g

    Use the following:

  • Olanzapineh
  • NK1 RA
  • 5-HT3 RAi,j
  • Dexametha-
    sonek,l

    Use the following:

  • Olan-
    zapineh on
    days 2-4
  • Oral aprepitant on days 2-3 (if oral aprepitant is used on day 1)
  • Dexametha-
    sonek,l
    on days 2-4
B

    Use the following:

  • Olanzapineh
  • Palonose-
    tron
  • Dexa-
    methasonek,l

    Use the following:

  • Olanzapineh
    on days 2-4
C

    Use the following:

  • NK1 RA
  • 5-HT3 RAi,j
  • Dexa-
    methasonek,l

    Use the following:

  • Oral aprepitant on days 2-3 (if oral aprepitant is used on day 1)
  • Dexa-
    methasonek,l
    on days 2-4

Adapted with permission from the NCCN Guidelines for Antiemesis V.1.2024. © 2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data become available. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

cFor details regarding recommendations and specific dosing information, please refer to the NCCN Guidelines for Antiemesis.

dAntiemetic regimens should be chosen based on the drug with the highest emetic risk as well as patient-specific risk factors.

eEspecially for patients with anticipatory, anxiety-related, or breakthrough nausea, may consider adding lorazepam 0.5–1 mg by mouth (PO) or IV or sublingual (SL) every 6 hours as needed on days 1–4. Use the lowest effective dose and dosage interval possible. May be administered with or without H2 blocker or proton pump inhibitor (PPI) if patient exhibits reflux symptoms.

fCategory 1 recommendations indicate uniform NCCN consensus that the intervention is appropriate based on high-level evidence.

gIf not used previously, consider escalating to a 4-drug regimen (option A) if emesis occurred during a previous cycle of anticancer therapy with a 3-drug regimen (olanzapine-containing regimen B or NK1 RA-containing regimen C). Olanzapine-containing regimens may be useful for patients with severe nausea.

hData suggest that a 5-mg dose of olanzapine is efficacious. Consider this dose especially for patients who are older or who are over sedated.

iIf netupitant/palonosetron or fosnetupitant/palonosetron fixed combination product is used, no further 5-HT3 RA is required.

jWhen used in combination with an NK1 RA, there is no preferred 5-HT3 RA.

kEmerging data and clinical practice suggest dexamethasone doses may be individualized. Higher doses may be considered, especially when an NK1 RA is not given concomitantly. Lower doses, given for shorter durations, or even elimination of dexamethasone on subsequent days (for delayed nausea and emesis prevention) may be acceptable based on patient characteristics. If dexamethasone is eliminated on subsequent days for delayed nausea and emesis prevention, consider other alternative antiemetics (eg, olanzapine).

lUse of corticosteroid premedications should be avoided with cellular therapies.

Nausea and vomiting toxicity grading criteria1,3

  • ENHERTU is highly emetogenic, which includes delayed nausea and/or vomiting. Administer prophylactic antiemetic medications per local institutional guidelines for prevention of chemotherapy-induced nausea and vomiting
  • NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Antiemesis recommendations may be found at NCCN.org (login required)
Severity Nausea Description
(NCI-CTCAE grading)
Vomiting Description
(NCI-CTCAE grading)
Grades 1 and 2
  • Grade 1: Loss of appetite without alteration in eating habits
  • Grade 2: Oral intake decreased without significant weight loss, dehydration, or malnutrition
  • Grade 1: Intervention not indicated
  • Grade 2: Outpatient IV hydration; medical intervention indicated
Grades 3 and 4
  • Grade 3: Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated
  • Grade 4: Not applicable
  • Grade 3: Tube feeding, TPN, or hospitalization indicated
  • Grade 4: Life-threatening consequences
Severity Nausea Description
(NCI-CTCAE grading)
Grades 1 and 2
  • Grade 1: Loss of appetite without alteration in eating habits
  • Grade 2: Oral intake decreased without significant weight loss, dehydration, or malnutrition
Grades 3 and 4
  • Grade 3: Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated
  • Grade 4: Not applicable
Severity Vomiting Description (NCI-CTCAE grading)
Grades 1 and 2
  • Grade 1: Intervention not indicated
  • Grade 2: Outpatient IV hydration; medical intervention indicated
Grades 3 and 4
  • Grade 3: Tube feeding, TPN, or hospitalization indicated
  • Grade 4: Life-threatening consequences

Fatigue toxicity grading criteria3,m

Severity Description (NCI-CTCAE grading)
Grades 1 and 2
  • Grade 1: Fatigue relieved by rest
  • Grade 2: Fatigue not relieved by rest; limiting instrumental activities of daily living
Grades 3 and 4
  • Grade 3: Fatigue not relieved by rest, limiting self-care activities of daily living
  • Grade 4: Not applicable
Severity Description (NCI-CTCAE grading)
Grades 1 and 2
  • Grade 1: Fatigue relieved by rest
  • Grade 2: Fatigue not relieved by rest; limiting instrumental activities of daily living
Grades 3 and 4
  • Grade 3: Fatigue not relieved by rest, limiting self-care activities of daily living
  • Grade 4: Not applicable

mIncluding fatigue, asthenia, and malaise.1

Alopecia toxicity grading criteria3,n

Severity Description (NCI-CTCAE grading)
Grade 1
  • Grade 1: Hair loss of <50% of normal for that individual that is not obvious from a distance but only on close inspection; a different hairstyle may be required to cover the hair loss but it does not require a wig or hairpiece to camouflage
Grade 2
  • Grade 2: Hair loss of ≥50% of normal for that individual that is readily apparent to others; a wig or hairpiece is necessary if the patient desires to completely camouflage the hair loss; associated with psychosocial impact
Severity Description (NCI-CTCAE grading)
Grade 1
  • Grade 1: Hair loss of <50% of normal for that individual that is not obvious from a distance but only on close inspection; a different hairstyle may be required to cover the hair loss but it does not require a wig or hairpiece to camouflage
Grade 2
  • Grade 2: Hair loss of ≥50% of normal for that individual that is readily apparent to others; a wig or hairpiece is necessary if the patient desires to completely camouflage the hair loss; associated with psychosocial impact

nPer NCI-CTCAE v.5.0, the highest NCI-CTCAE grade for alopecia is Grade 2.3

Constipation toxicity grading criteria3

Severity Description (NCI-CTCAE grading)
Grades 1 and 2
  • Grade 1: Occasional or intermittent symptoms; occasional use of stool softeners, laxatives, dietary modification, or enema
  • Grade 2: Persistent symptoms with regular use of laxatives or enemas, limiting instrumental activities of daily living
Grades 3 and 4
  • Grade 3: Obstipation with manual evacuation indicated; limiting self-care activities of daily living
  • Grade 4: Life-threatening consequences; urgent intervention indicated
Severity Description (NCI-CTCAE grading)
Grades 1 and 2
  • Grade 1: Occasional or intermittent symptoms; occasional use of stool softeners, laxatives, dietary modification, or enema
  • Grade 2: Persistent symptoms with regular use of laxatives or enemas, limiting instrumental activities of daily living
Grades 3 and 4
  • Grade 3: Obstipation with manual evacuation indicated; limiting self-care activities of daily living
  • Grade 4: Life-threatening consequences; urgent intervention indicated

Decreased appetite toxicity grading criteria3

Severity Description (NCI-CTCAE grading)
Grades 1 and 2
  • Grade 1: Loss of appetite without alteration in eating habits
  • Grade 2: Oral intake altered without significant weight loss or malnutrition, oral nutrition supplements indicated
Grades 3 and 4
  • Grade 3: Associated with significant weight loss or malnutrition (eg, inadequate oral caloric and/or fluid intake): tube feeding or TPN indicated
  • Grade 4: Life-threatening consequences, urgent intervention indicated
Severity Description (NCI-CTCAE grading)
Grades 1 and 2
  • Grade 1: Loss of appetite without alteration in eating habits
  • Grade 2: Oral intake altered without significant weight loss or malnutrition, oral nutrition supplements indicated
Grades 3 and 4
  • Grade 3: Associated with significant weight loss or malnutrition (eg, inadequate oral caloric and/or fluid intake): tube feeding or TPN indicated
  • Grade 4: Life-threatening consequences, urgent intervention indicated

Diarrhea toxicity grading criteria3

Severity Description (NCI-CTCAE grading)
Grades 1 and 2
  • Grade 1: Increase of <4 stools per day over baseline; mild increase in ostomy output compared to baseline
  • Grade 2: Increase of 4-6 stools per day over baseline; moderate increase in ostomy output compared to baseline; limiting instrumental activities of daily living
Grades 3 and 4
  • Grade 3: Increase of ≥7 stools per day over baseline; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self-care activities of daily living
  • Grade 4: Life-threatening consequences; urgent intervention indicated
Severity Description (NCI-CTCAE grading)
Grades 1 and 2
  • Grade 1: Increase of <4 stools per day over baseline; mild increase in ostomy output compared to baseline
  • Grade 2: Increase of 4-6 stools per day over baseline; moderate increase in ostomy output compared to baseline; limiting instrumental activities of daily living
Grades 3 and 4
  • Grade 3: Increase of ≥7 stools per day over baseline; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self-care activities of daily living
  • Grade 4: Life-threatening consequences; urgent intervention indicated

Events were graded using NCI-CTCAE v.5.0.3

5-HT3, 5-hydroxytryptamine 3; aGC, advanced gastric cancer; AR, adverse reaction; FDA, Food and Drug Administration; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ILD, interstitial lung disease; IV, intravenous; mBC, metastatic breast cancer; mNSCLC, metastatic non-small cell lung cancer; NCCN, National Comprehensive Cancer Network® (NCCN®); NCI-CTCAE, National Cancer Institute–Common Terminology Criteria for Adverse Events; NSCLC, non-small cell lung cancer; Q3W, every 3 weeks; NK1, neurokinin-1; RA, receptor antagonist; TPN, total parenteral nutrition.

WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY

  • Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms.
  • Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.
INDICATIONS

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:

  • Unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either:
    • In the metastatic setting, or
    • In the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy
  • Unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy
  • Unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy

    This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

  • Locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen
  • Unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options

    This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Contraindications

None.

Warnings and Precautions

Interstitial Lung Disease / Pneumonitis

Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU. A higher incidence of Grade 1 and 2 ILD/pneumonitis has been observed in patients with moderate renal impairment. Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in ≤28 days from date of onset, maintain dose. If resolved in >28 days from date of onset, reduce dose one level. Consider corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., ≥0.5 mg/kg/day prednisolone or equivalent). For symptomatic ILD/pneumonitis (Grade 2 or greater), permanently discontinue ENHERTU. Promptly initiate systemic corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., ≥1 mg/kg/day prednisolone or equivalent) and continue for at least 14 days followed by gradual taper for at least 4 weeks.

HER2-Positive or HER2-Low Metastatic Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg)

In patients with metastatic breast cancer, HER2-mutant NSCLC, and other solid tumors treated with ENHERTU 5.4 mg/kg, ILD occurred in 12% of patients. Median time to first onset was 5.5 months (range: 0.9 to 31.5). Fatal outcomes due to ILD and/or pneumonitis occurred in 1.0% of patients treated with ENHERTU.

HER2-Positive Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg)

In patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, ILD occurred in 10% of patients. Median time to first onset was 2.8 months (range: 1.2 to 21).

Neutropenia

Severe neutropenia, including febrile neutropenia, can occur in patients treated with ENHERTU. Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated. For Grade 3 neutropenia (Absolute Neutrophil Count [ANC] <1.0 to 0.5 x 109/L), interrupt ENHERTU until resolved to Grade 2 or less, then maintain dose. For Grade 4 neutropenia (ANC <0.5 x 109/L), interrupt ENHERTU until resolved to Grade 2 or less, then reduce dose by one level. For febrile neutropenia (ANC <1.0 x 109/L and temperature >38.3º C or a sustained temperature of ≥38º C for more than 1 hour), interrupt ENHERTU until resolved, then reduce dose by one level.

HER2-Positive or HER2-Low Metastatic Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg)

In patients with metastatic breast cancer, HER2-mutant NSCLC, and other solid tumors treated with ENHERTU 5.4 mg/kg, a decrease in neutrophil count was reported in 63% of patients. Seventeen percent had Grade 3 or 4 decreased neutrophil count. Median time to first onset of decreased neutrophil count was 22 days (range: 2 to 939). Febrile neutropenia was reported in 1% of patients.

HER2-Positive Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg)

In patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, a decrease in neutrophil count was reported in 72% of patients. Fifty-one percent had Grade 3 or 4 decreased neutrophil count. Median time to first onset of decreased neutrophil count was 16 days (range: 4 to 187). Febrile neutropenia was reported in 4.8% of patients.

Left Ventricular Dysfunction

Patients treated with ENHERTU may be at increased risk of developing left ventricular dysfunction. Left ventricular ejection fraction (LVEF) decrease has been observed with anti-HER2 therapies, including ENHERTU. Assess LVEF prior to initiation of ENHERTU and at regular intervals during treatment as clinically indicated. Manage LVEF decrease through treatment interruption. When LVEF is >45% and absolute decrease from baseline is 10-20%, continue treatment with ENHERTU. When LVEF is 40-45% and absolute decrease from baseline is <10%, continue treatment with ENHERTU and repeat LVEF assessment within 3 weeks. When LVEF is 40-45% and absolute decrease from baseline is 10-20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF has not recovered to within 10% from baseline, permanently discontinue ENHERTU. If LVEF recovers to within 10% from baseline, resume treatment with ENHERTU at the same dose. When LVEF is <40% or absolute decrease from baseline is >20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF of <40% or absolute decrease from baseline of >20% is confirmed, permanently discontinue ENHERTU. Permanently discontinue ENHERTU in patients with symptomatic congestive heart failure. Treatment with ENHERTU has not been studied in patients with a history of clinically significant cardiac disease or LVEF <50% prior to initiation of treatment.

HER2-Positive or HER2-Low Metastatic Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg)

In patients with metastatic breast cancer, HER2-mutant NSCLC, and other solid tumors treated with ENHERTU 5.4 mg/kg, LVEF decrease was reported in 3.8% of patients, of which 0.6% were Grade 3.

HER2-Positive Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg)

In patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, no clinical adverse events of heart failure were reported; however, on echocardiography, 8% were found to have asymptomatic Grade 2 decrease in LVEF.

Embryo-Fetal Toxicity

ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. Verify the pregnancy status of females of reproductive potential prior to the initiation of ENHERTU. Advise females of reproductive potential to use effective contraception during treatment and for 7 months after the last dose of ENHERTU. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for 4 months after the last dose of ENHERTU.

Additional Dose Modifications

Thrombocytopenia

For Grade 3 thrombocytopenia (platelets <50 to 25 x 109/L) interrupt ENHERTU until resolved to Grade 1 or less, then maintain dose. For Grade 4 thrombocytopenia (platelets <25 x 109/L) interrupt ENHERTU until resolved to Grade 1 or less, then reduce dose by one level.

Adverse Reactions

HER2-Positive and HER2-Low Metastatic Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg)

The pooled safety population reflects exposure to ENHERTU 5.4 mg/kg intravenously every 3 weeks in 1799 patients in Study DS8201-A-J101 (NCT02564900), DESTINY-Breast01, DESTINY-Breast02, DESTINY-Breast03, DESTINY-Breast04, DESTINY-Lung01, DESTINY-Lung02, DESTINY-CRC02, and DESTINY-PanTumor02. Among these patients, 65% were exposed for >6 months and 38% were exposed for >1 year. In this pooled safety population, the most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea (73%), decreased white blood cell count (70%), decreased hemoglobin (66%), decreased neutrophil count (63%), decreased lymphocyte count (58%), fatigue (56%), decreased platelet count (48%), increased aspartate aminotransferase (47%), increased alanine aminotransferase (43%), vomiting (40%), increased blood alkaline phosphatase (38%), alopecia (34%), constipation (33%), decreased appetite (32%), decreased blood potassium (31%), diarrhea (29%), musculoskeletal pain (24%), and abdominal pain (20%).

HER2-Positive Metastatic Breast Cancer

DESTINY-Breast03

The safety of ENHERTU was evaluated in 257 patients with unresectable or metastatic HER2-positive breast cancer who received at least one dose of ENHERTU 5.4 mg/kg intravenously once every three weeks in DESTINY-Breast03. The median duration of treatment was 14 months (range: 0.7 to 30).

Serious adverse reactions occurred in 19% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were vomiting, interstitial lung disease, pneumonia, pyrexia, and urinary tract infection. Fatalities due to adverse reactions occurred in 0.8% of patients including COVID-19 and sudden death (one patient each).

ENHERTU was permanently discontinued in 14% of patients, of which ILD/pneumonitis accounted for 8%. Dose interruptions due to adverse reactions occurred in 44% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, leukopenia, anemia, thrombocytopenia, pneumonia, nausea, fatigue, and ILD/pneumonitis. Dose reductions occurred in 21% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were nausea, neutropenia, and fatigue.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea (76%), decreased white blood cell count (74%), decreased neutrophil count (70%), increased aspartate aminotransferase (67%), decreased hemoglobin (64%), decreased lymphocyte count (55%), increased alanine aminotransferase (53%), decreased platelet count (52%), fatigue (49%), vomiting (49%), increased blood alkaline phosphatase (49%), alopecia (37%), decreased blood potassium (35%), constipation (34%), musculoskeletal pain (31%), diarrhea (29%), decreased appetite (29%), headache (22%), respiratory infection (22%), abdominal pain (21%), increased blood bilirubin (20%), and stomatitis (20%).

HER2-Low Metastatic Breast Cancer

DESTINY-Breast04

The safety of ENHERTU was evaluated in 371 patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who received ENHERTU 5.4 mg/kg intravenously once every 3 weeks in DESTINY-Breast04. The median duration of treatment was 8 months (range: 0.2 to 33) for patients who received ENHERTU.

Serious adverse reactions occurred in 28% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were ILD/pneumonitis, pneumonia, dyspnea, musculoskeletal pain, sepsis, anemia, febrile neutropenia, hypercalcemia, nausea, pyrexia, and vomiting. Fatalities due to adverse reactions occurred in 4% of patients including ILD/pneumonitis (3 patients); sepsis (2 patients); and ischemic colitis, disseminated intravascular coagulation, dyspnea, febrile neutropenia, general physical health deterioration, pleural effusion, and respiratory failure (1 patient each).

ENHERTU was permanently discontinued in 16% of patients, of which ILD/pneumonitis accounted for 8%. Dose interruptions due to adverse reactions occurred in 39% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, fatigue, anemia, leukopenia, COVID-19, ILD/pneumonitis, increased transaminases, and hyperbilirubinemia. Dose reductions occurred in 23% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, thrombocytopenia, and neutropenia.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea (76%), decreased white blood cell count (70%), decreased hemoglobin (64%), decreased neutrophil count (64%), decreased lymphocyte count (55%), fatigue (54%), decreased platelet count (44%), alopecia (40%), vomiting (40%), increased aspartate aminotransferase (38%), increased alanine aminotransferase (36%), constipation (34%), increased blood alkaline phosphatase (34%), decreased appetite (32%), musculoskeletal pain (32%), diarrhea (27%), and decreased blood potassium (25%).

HER2-Mutant Unresectable or Metastatic NSCLC (5.4 mg/kg)

DESTINY-Lung02 evaluated two dose levels (5.4 mg/kg [n=101] and 6.4 mg/kg [n=50]); however, only the results for the recommended dose of 5.4 mg/kg intravenously every 3 weeks are described below due to increased toxicity observed with the higher dose in patients with NSCLC, including ILD/pneumonitis.

The safety of ENHERTU was evaluated in 101 patients with HER2-mutant unresectable or metastatic NSCLC who received ENHERTU 5.4 mg/kg intravenously once every three weeks until disease progression or unacceptable toxicity in DESTINY-Lung02. Nineteen percent of patients were exposed for >6 months.

Serious adverse reactions occurred in 30% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were ILD/pneumonitis, thrombocytopenia, dyspnea, nausea, pleural effusion, and increased troponin I. Fatality occurred in 1 patient with suspected ILD/pneumonitis (1%).

ENHERTU was permanently discontinued in 8% of patients. Adverse reactions which resulted in permanent discontinuation of ENHERTU were ILD/pneumonitis, diarrhea, decreased blood potassium, hypomagnesemia, myocarditis, and vomiting. Dose interruptions of ENHERTU due to adverse reactions occurred in 23% of patients. Adverse reactions which required dose interruption (>2%) included neutropenia and ILD/pneumonitis. Dose reductions due to an adverse reaction occurred in 11% of patients.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea (61%), decreased white blood cell count (60%), decreased hemoglobin (58%), decreased neutrophil count (52%), decreased lymphocyte count (43%), decreased platelet count (40%), decreased albumin (39%), increased aspartate aminotransferase (35%), increased alanine aminotransferase (34%), fatigue (32%), constipation (31%), decreased appetite (30%), vomiting (26%), increased alkaline phosphatase (22%), and alopecia (21%).

HER2-Positive Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg)

The safety of ENHERTU was evaluated in 187 patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma in DESTINY-Gastric01. Patients intravenously received at least one dose of either ENHERTU (N=125) 6.4 mg/kg every 3 weeks or either irinotecan (N=55) 150 mg/m2 biweekly or paclitaxel (N=7) 80 mg/m2 weekly for 3 weeks. The median duration of treatment was 4.6 months (range: 0.7 to 22.3) for patients who received ENHERTU.

Serious adverse reactions occurred in 44% of patients receiving ENHERTU 6.4 mg/kg. Serious adverse reactions in >2% of patients who received ENHERTU were decreased appetite, ILD, anemia, dehydration, pneumonia, cholestatic jaundice, pyrexia, and tumor hemorrhage. Fatalities due to adverse reactions occurred in 2.4% of patients: disseminated intravascular coagulation, large intestine perforation, and pneumonia occurred in one patient each (0.8%).

ENHERTU was permanently discontinued in 15% of patients, of which ILD accounted for 6%. Dose interruptions due to adverse reactions occurred in 62% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, anemia, decreased appetite, leukopenia, fatigue, thrombocytopenia, ILD, pneumonia, lymphopenia, upper respiratory tract infection, diarrhea, and decreased blood potassium. Dose reductions occurred in 32% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were neutropenia, decreased appetite, fatigue, nausea, and febrile neutropenia.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased hemoglobin (75%), decreased white blood cell count (74%), decreased neutrophil count (72%), decreased lymphocyte count (70%), decreased platelet count (68%), nausea (63%), decreased appetite (60%), increased aspartate aminotransferase (58%), fatigue (55%), increased blood alkaline phosphatase (54%), increased alanine aminotransferase (47%), diarrhea (32%), decreased blood potassium (30%), vomiting (26%), constipation (24%), increased blood bilirubin (24%), pyrexia (24%), and alopecia (22%).

HER2-Positive (IHC3+) Unresectable or Metastatic Solid Tumors

The safety of ENHERTU was evaluated in 347 adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who received ENHERTU 5.4 mg/kg intravenously once every 3 weeks in DESTINY-Breast01, DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02. The median duration of treatment was 8.3 months (range 0.7 to 30.2).

Serious adverse reactions occurred in 34% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were sepsis, pneumonia, vomiting, urinary tract infection, abdominal pain, nausea, pneumonitis, pleural effusion, hemorrhage, COVID-19, fatigue, acute kidney injury, anemia, cellulitis, and dyspnea. Fatalities due to adverse reactions occurred in 6.3% of patients including ILD/pneumonitis (2.3%), cardiac arrest (0.6%), COVID-19 (0.6%), and sepsis (0.6%). The following events occurred in one patient each (0.3%): acute kidney injury, cerebrovascular accident, general physical health deterioration, pneumonia, and hemorrhagic shock.

ENHERTU was permanently discontinued in 15% of patients, of which ILD/pneumonitis accounted for 10%. Dose interruptions due to adverse reactions occurred in 48% of patients. The most frequent adverse reactions (>2%) associated with dose interruption were decreased neutrophil count, anemia, COVID-19, fatigue, decreased white blood cell count, and ILD/pneumonitis. Dose reductions occurred in 27% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, decreased neutrophil count, ILD/pneumonitis, and diarrhea.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased white blood cell count (75%), nausea (69%), decreased hemoglobin (67%), decreased neutrophil count (66%), fatigue (59%), decreased lymphocyte count (58%), decreased platelet count (51%), increased aspartate aminotransferase (45%), increased alanine aminotransferase (44%), increased blood alkaline phosphatase (36%), vomiting (35%), decreased appetite (34%), alopecia (34%), diarrhea (31%), decreased blood potassium (29%), constipation (28%), decreased sodium (22%), stomatitis (20%), and upper respiratory tract infection (20%).

Use in Specific Populations

  • Pregnancy: ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. There are clinical considerations if ENHERTU is used in pregnant women, or if a patient becomes pregnant within 7 months after the last dose of ENHERTU.
  • Lactation: There are no data regarding the presence of ENHERTU in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ENHERTU and for 7 months after the last dose.
  • Females and Males of Reproductive Potential: Pregnancy testing: Verify pregnancy status of females of reproductive potential prior to initiation of ENHERTU. Contraception: Females: ENHERTU can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with ENHERTU and for 7 months after the last dose. Males: Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for 4 months after the last dose. Infertility: ENHERTU may impair male reproductive function and fertility.
  • Pediatric Use: Safety and effectiveness of ENHERTU have not been established in pediatric patients.
  • Geriatric Use: Of the 1287 patients with HER2-positive or HER2-low breast cancer treated with ENHERTU 5.4 mg/kg, 22% were ≥65 years and 3.8% were ≥75 years. No overall differences in efficacy within clinical studies were observed between patients ≥65 years of age compared to younger patients. There was a higher incidence of Grade 3-4 adverse reactions observed in patients aged ≥65 years (59%) as compared to younger patients (49%). Of the 101 patients with HER2-mutant unresectable or metastatic NSCLC treated with ENHERTU 5.4 mg/kg, 40% were ≥65 years and 8% were ≥75 years. No overall differences in efficacy or safety were observed between patients ≥65 years of age compared to younger patients. Of the 125 patients with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg in DESTINY-Gastric01, 56% were ≥65 years and 14% were ≥75 years. No overall differences in efficacy or safety were observed between patients ≥65 years of age compared to younger patients. Of the 192 patients with HER2-positive (IHC 3+) unresectable or metastatic solid tumors treated with ENHERTU 5.4 mg/kg in DESTINY-PanTumor02, DESTINY-Lung01, or DESTINY-CRC02, 39% were 65 years or older and 9% were 75 years or older. No overall differences in efficacy or safety were observed between patients ≥65 years of age compared to younger patients.
  • Renal Impairment: A higher incidence of Grade 1 and 2 ILD/pneumonitis has been observed in patients with moderate renal impairment. Monitor patients with moderate renal impairment more frequently. The recommended dosage of ENHERTU has not been established for patients with severe renal impairment (CLcr <30 mL/min).
  • Hepatic Impairment: In patients with moderate hepatic impairment, due to potentially increased exposure, closely monitor for increased toxicities related to the topoisomerase inhibitor, DXd. The recommended dosage of ENHERTU has not been established for patients with severe hepatic impairment (total bilirubin >3 times ULN and any AST).

To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch.

Please click here for full Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

INDICATIONS

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:

  • Unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either:
    • In the metastatic setting, or
    • In the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy
  • Unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy
  • Unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy

    This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

  • Locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen
  • Unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options

    This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

References
  • ENHERTU. Prescribing information. Daiichi Sankyo, Inc.; 2024.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis V.1.2024. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed December 13, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Published November 27, 2017.
Back to top